Allogene Therapeutics announced positive early Phase 1 results for ALLO-329, an off-the-shelf allogeneic CAR T therapy targeting autoimmune diseases like systemic sclerosis (scleroderma). In 18 patients, ALLO-329 showed a favorable safety profile with no severe toxicities and demonstrated clinical improvements in skin symptoms for 8 of 10 scleroderma patients, many of whom stopped immunosuppressive therapy. The trial explores different lymphodepletion regimens, including none, to optimize treatment safety and efficacy. Further data is expected in 2027 as dose escalation continues.
Allogene Therapeutics' early clinical data on ALLO-329 provides context for readers interested in health sector trends. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 18 fell. Notable movers include ROIV at USD 40.25 (+3.52%), NUWE at USD 4.72 (+3.06%), and CTXR at USD 0.54 (-2.98%).
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
